rhDNase I

DRUG3 trials

Sponsors

University of Illinois at Chicago, McGill University Health Centre/Research Institute of the McGill University Health Centre, Tel-Aviv Sourasky Medical Center

Conditions

COVID-19 InfectionDry EyeLarge B-Cell Lymphoma (LBCL)Ocular Graft vs Host Disease

Phase 1

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

TerminatedNCT02702518

University of Illinois at ChicagoDry Eye, Ocular Graft vs Host Disease

Start: 2016-04-30End: 2020-04-08Updated: 2021-09-05

DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)

CompletedNCT04409925

McGill University Health Centre/Research Institute of the McGill University Health CentreCOVID-19 Infection

Start: 2020-12-25End: 2021-08-01Updated: 2023-03-17

Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.

RecruitingNCT07361224

Tel-Aviv Sourasky Medical CenterLarge B-Cell Lymphoma (LBCL)

Start: 2026-05-01End: 2028-02-01Target: 12Updated: 2026-05-01